Latest Commercialization Strategy News

Page 11 of 17
Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.
Ada Torres
Ada Torres
4 Sept 2025
PolyNovo Limited stands to benefit from proposed U.S. Medicare changes that introduce a flat reimbursement rate for outpatient wound care skin substitutes, potentially reshaping the competitive landscape in favour of cost-effective, clinically proven products.
Ada Torres
Ada Torres
2 Sept 2025
SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.
Ada Torres
Ada Torres
29 Aug 2025
Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.
Ada Torres
Ada Torres
28 Aug 2025
AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.
Maxwell Dee
Maxwell Dee
28 Aug 2025
ARN Media reported a 7% revenue decline in the first half of FY25 amid audience challenges and a sluggish post-election market, yet digital audio revenue surged 21%. A $40 million transformational cost-out program and leadership overhaul set the stage for a strategic reset and growth in the second half.
Elise Vega
Elise Vega
27 Aug 2025
Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.
Maxwell Dee
Maxwell Dee
26 Aug 2025
An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.
Ada Torres
Ada Torres
25 Aug 2025
BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.
Sophie Babbage
Sophie Babbage
22 Aug 2025